STABLE HEMOGLOBIN BASED COMPOSITION AND METHOD TO STORE SAME

Abstract: The present invention relates to a stable hemoglobin based composition having sufficiently low levels of methemoglobin to effectively function as an oxygen carrying solution upon administration to a patient made by the process comprising: a) adding an oxygenated or deoxygenated form of said blood substitute to an oxygen impermeable package, and b) storing said container at from between 5 DEG C to 45 DEG C for sufficient time to permit the autoreduction of methemoglobin. The stable hemoglobin based composition includes hemoglobin, modified hemoglobin and/or encapsulated hemoglobin. To effectively function as an oxygen carrying solution upon administration to a patient, the stable hemolobin based solution cannot have greater than about 50 % of said hemoglobin based solution in the methemoglobin form but, preferably no more than about 15 %. The invention further relates to a method to store a stable oxygen carrying solution according to the above discussed process.

Description: STABLE HEMOGLOBIN BASED COMPOSITION AND METHOD TO STORE SflME Background of the Invention Field of the Invention This invention relates to a stable hemoglobin-based oxygen- carrying cat-position and methods to store or process same, said hemoglobin ccrcpositiαn including hemoglobin, modified hemoglobin and encapsulated hemoglobin. Description of Related Art Although human whole blood and packed red cell preparations have long been used to restore body oxygen-carrying function, hemoglobin-based compositions are now seen to offer several advantages over these currently standard hemotherapies. Patient safety would be enhanced by eliminating untoward reactions to biood group antigens, improving the maintenance of systemic acid- base and electrolyte balance, and avoiding exposure to blood contaminated with diseases such as AIDS and hepatitis. The high costs of testing blood for blood group antigens and disease factors would also be avoided. Further, hemoglobin-based oxygen- carrying substitutes are expected to have prolonged stability during storage so a more stable supply should be realized. While a number of parameters may be measured to characterize hemoglobin solution stability, such as oxygen carrying capacity and ionic composition, the most important of these is the oxidation state of hemoglobin iron. The iron atom in each of the hesne prosthetic groups of the hemoglobin molecule is the site of oxygen binding and release. In order to maintain this reversible oxygen binding capability, the heme iron must be in the physiological Fe state. When a solution of hemoglobin is stored for a long period of time, the iron tends to oxidize to the Fe state, giving the methemoglobin form which does not reversibiy bind oxygen and is therefore physiologically ineffective. (Ξ.F. Bunn et al. Hemoglobin: Moleσαlar Genetic and Clinical Aspects 640 (1986)). One current strategy to prevent the above described hemoglobin autoxidation reaction is the addition of anti-oxidants (Stratton, L.P., Hemoglobin 12(4):353-368(1988)) such as NADH (Kajita, A. et al., Biochem. Biophys. Res. Ccran. 39:1199(1970)). However, in hemoglobin solutions some anti-oxidants can become pro-oxidants (ibid. Stratton et al.) . Further, the addition of a component to an intravenous solution product ccπplicates manufacture and raises issues of the toxicity of the new component which can require costly testing during deveioprsent. .0 The active reduction of methemoglobin in solution can be accomplished by electrochemical means (P. Schelier, Mechanism of Cathodic Reduction of Hemoproteins, 60 Studia Biophysica 137 (Berlin) (1976)), the use of reductive enzyme systems (Hayashi. A. et al. Biochem. Biophys. Acta 310:309(1973)) or the addition of 5 chemical reducing agents such as ascorbate (Tcmoda, A. et al., J. Biol. Chem. 253 (20):7415-7419 (1978)). These systems all require chemical additives and suffer from the same limitations mentioned above for anti-oxidants. Aviable hemoglobinbased oxygen-carrying composition should :0 contain less than 50% and preferably less than 15% methemoglobin over the shelf life. The rate of hemoglobin auto-oxidatiαn is, of course, dependent on teπperature. Thus,at roαn temperature (25°C) heme iron oxidation can exceed 30% per day (See Devenuto, F. , infra at 946). Consequently, hemoglobin based oxygen carrying 5 compositions are typically stored in the frozen state to obtain the targeted shelf-life. The extent of hemoglobin protein purity is an important s consideration in any discussion of hemoglobin stability in solution. Hemoglobin heme iron is continuously oxidized .in vivo 0 and the red cell contains enzyme systems ' that directly reduce ■ methemoglobin to restore hemoglobin function. (Huitquist, D.E. et al. , The Methemoglobin Reduction System of Ξrythrocyte , in The International Conference on Red Cell Metabolism and Function, 297- 301; U iv. of Michigan (1974)). Paul, H.B. et al. Preparation oi Hemoglobin Solutions for Intraveneous Infusions, 455, 463 (1947; Other red cell enzymes eliminate activated oxygen products, such as superoxide and hydrogen peroxide, that can also oxidize heme iron. (Watkins J.A. et al., Biochem. Biophys. Res. Ccmr.. 132(2):742-748 (1985)). It is not surprising therefore that less pure preparations of hemoglobin exhibit increased oxidation stability, particularly when the native methemoglobin reductase substrates, such as ADH, are added to the preparation (Stratton, L.P. et al., Hemoglobin 12(4):353-368 (1988)). Despite this oxidative protection in impure preparations, contaminating proteins can cause iir unogenic reactions in patients or may possess innate toxic properties when free in the circulation. Thus, a system that could provide oxidation stability and/or reduce methemoglobin in purified hemoglobin preparations, over a broad temperature range, would possess a substantial advantage. Surrmary of the Invention This invention relates to methods to obtain a set of conditions as delineated below, that allow the expression of a hemoglobin autoreduction reaction that spontaneously converts methemoglobin to deoxyhemoglobin in purified hemoglobin preparations. This autoreduction reaction is accelerated at higher temperatures, and as lonr as the proper conditions are maintained as delineated below, the system provides oxidation stability at room temperature. Thepresent invention relates to a purified hemoglobin based cocrposition having sufficiently low levels of methemoglobin to effectively function as an oxygen-carrying composition upon administration to a patient. The composition is made by a process comprising: a) adding a pμrified hemoglobin based oxygen-carrying composition to a substantially oxygen impermeable container, b) storing said container at from between 5°C to 45°C for sufficient time to permit autoreduction of methemoglobin, and σ) storing said container at a final torage temperature between -270 " C and 45 ' C. The purified hemoglobin based composition includes hemoglobin, modified hemoglobin and/or encapsulated hemogiobir. preparations that have been purified. Purification can be according to εn known standard method such as heat treatment. (See Ξstεp, U.S. Patent Nos. 4,861,867 and 4,831,012 (incorporated by reference)). To effectively restore body oxygen-carrying function, it is presently believed that a stable hemoglobin based composition cannot have greater than about 50%, and preferably less than 15%, of the composition in the methemoglobin form. It is an object of this invention to be able to store a stablehemoglobin based composition over a wide temperature range. It is further an object of this invention to stop methemoglobin production and in fact cause Fe methemoglobin to convert to reduced Per hemoglobin in said ccπposition. It is further an object of this invention to store a purified hemoglobin based composition in a system that either substantially excludes and/or actively scavenges oxygen, thus allowing the autoreduction reaction to predominate over autoxidation. It is still another object of this invention to provide a system of oxygen removal that does not require pretreatment or entry into the storage system. The hemoglobin solution, whichmay contain an amount of methemoglobin, is stored in a container that is substantially impermeable to oxygen. In this substantially impermeable oxygen environment the hemoglobin autoxidation reaction will consume any oxygen in solution, deoxygenate the remaining Per hemoglobin and allow autoreduction of any methemoglobin to proceed. It is still another object of this invention to store a purified hemoglobin based ccnpositicn in the oxygenated form and allow deoxygenation in the,container to permit autoreduction. It is still another object of the system to salvage batches of purified hemoglobin based composition in which unacceptable levels of oxidation have occurred. In this case the purified hemoglobin based composition could be stored in bulk in a substantially impermeable container. It is still another object of this invention to store the deoxygenated, purified hemoglobin based composition in any system which allows diffusion of oxygen from the solution into an area surrounding the container but not outside a substantially oxygen iπpermeable outer container. Brief Description of Drawings For a fuller understanding of the nature and objects of the invention, reference should be made to the following detailed description taken in connection with the accompanying description forming a part of this specification. FIG. 1 shows the changes in concentration of hemoglobin moieties versus time in a solution of diaspirin alpha-alpha cross- linked hemoglobin in lactated Ringer's (total diaspirin cross- linked hemoglobin concentration of approximately 39μM) that was sealed in a screw-topped cuvette (no head-space) and kept at 25°C. FIG. 2 shows changes in mean percent hemoglobin moieties versus time in sealed screw-capped cuvettes (N = 4) that were filled completelywith a deoxygenated solution of diaspirin cross- linked hemoglobin in lactated Ringer's (total diaspirin cross- linked hemoglobin concentration of approximately 38μ) and kept at 25 * C. FIG. 3 shows the changes in hemoglobin moieties and total hemoglobin versus time in a deoxygenated solution of diaspirin cross-linked hemoglobin in lOirM phosphate buffer that was sealed in a screw-capped cuvette (no head space) and kept at 25'C. FIG. 4 shows the changes in hemoglobin moieties and total hemoglobin versus time in a solution of diaspirin cross-linked hemoglobin in lactated Ringer's that was equilibrated with air and sealed in a screw-capped cuvette with no head space and kept at 25 * C. FIG. 5 shows the changes in percent methemoglobin versus time ir. a solution of lOg/dl ciaspirir. cross-linked hemogiobir. in lactated Ringer's. The control group units were not deoxygenated and were either sealed in foil pouches (Ambient Pouched) or not (Ambient Not Pouched). All units were kept at 25 " C. FIG. 6 shows the changes in percent methemoglobin versus time in a deoxygenated solution of lOg/dl diaspirin cross-linked hemoglobin in lactated Ringer's, units in the three test rσjpϊ units were stored at 5°C with one 100ml capacity oxygen absorbing packet in the foil pouch, 25 * C with one 100ml packet or 25°C with four 100ml packets. Control group units were stored at 25 * C with no oxygen absorbing packets in the foil pouch. FIG. 7 shows the changes in percent methemoglobin versus time in a deoxygenated solution of 10 g/dl diaspirin cross-linked hemoglobin in lactated Ringer's. The packaging of the solution was carried out as in Example 6 above. Test group units contained a 200 ml capacity oxygen absorbing packet in the foil pouch and were stored at 5 * C, 25 β C, 30"C, or 45 * C. Control group unit storage at 25°C was without oxygen packets. Units in ail groups were stored at 25 * C. FIG. 8 shows the changes in percent methemoglobin versus time in a deoxygenated solution of 10 g/dl diaspirin cross-linked hemoglobin in lactated Ringer's. Test group units contained 200, 400 or 800 ml of oxygen absorbing capacity while the control group units contained no packets. Detailed Description of the Invention - Best Mode We have observed that in deoxygenated solutions of purified hemoglobin, oxidized Fer methemoglobin heme iron will spontaneously reduce to the physiologically useful Fe 24 form. Based on this discovery we have developed a packaging and storage system that allows the expression of the autoreduction reaction. The components necessary to perform the packaging operation are sealed in an isolator (glove chamber) . These ccrcponents would include, for exanple, plastic bag primary containers for the hemoglobin solution, outer wrap secondary containers that have very low oxygen permeability, puπps, clamps, tubing assemblies, ε solution reservoir, and oxygen monitors. The isolator interior is sterilized with a vaporized sterilant such as H-O ? and then cleared of residual sterilant with low-oxygen grade nitrogen. Oxygen is then rigorously removed from the isolator by carefully purging the isolator interior and all components within it with nitrogen. Preferably, at this stage ultra-pure grade nitrogen would be used with in-line oxygen traps to attain very low oxygen levels. In the now low oxygen environment of the isolator, the plastic primary containers are filled with aliquots of a thoroughly deoxygenated hemoglobin solution and then sealed in foil pouch secondary containers. When this operation is completed the isolator is opened and the containers are placed in storage. Although autoreduction has been observed to take place during the deoxygenation of the hemoglobin solution, and can be taken advantage of in this way, the reaction proceeds readily during storage in a substantially oxygen iπpermeable package and requires no further attention. After hemoglobin solutions are prepared and packaged as described above, there is typically a period of two to five days before the onset of autoreduction. During this time residual oxygen is scavenged from the solution by the oxidation reaction. Consequently, this oxygen scavenging phase is characterized by either an increase in methemoglobin or, if deoxygenation of the solution and packaging components was rigorous enough, a time during which methemoglobin remains at the initial level. The latter case occurs when oxygen has been reduced to a level at which the rates of autoxidation and autoreduction are equal. The duration of this oxygen scavenging phase is temperature dependent, ranging from less than one day at 45"C to months at 5 * C. After the oxygen scavenging phase the methemoglobin level begins to decrease and this trend continues in an essentially linear manner to a minimum, generally less than 5% methemoglobin, that is maintained as long as oxygen is substantially excluded. The acceptable temperature range for reducing methemogiobir. in a purified hemoglobin composition during storage is between 5"C, where the autoreduction reaction is very slow, to less than 45'C above which other degradant reactions can limit shelf-life. Roomtemperature oxidation stability is achieved with this system. Among the exaπples below, ongoing experiments are described in which, subsequent to the oxygen-scavenging phase, methemoglobin has been maintained at less than three percent for 231 days at 25 * C. It should be noted that once methemoglobin concentration is sufficiently low to allow said hemoglobin solution to effectively function as an oxygen carrying solution the solution can be stored at from between -270"C to 45"C. Example 1 In this experiment a dilute solution of alpha-alpha cross- linked hemoglobin was sealed in screw-capped cuvettes and kept at 25°C. With a dilute solution (approximately 39 γ ~ i diaspirin cross-linked hemoglobin) in a cuvette it was possible to noninvasively observe changes in the concentrations of oxy-, deoxy-, met- and total hemoglobin during storage using a standard three-wavelength spectre-photometric method taking measurements at 560, 576 and 630nm. All manipulations to prepare samples were carried out in a glove-bag continuouslypurged with ultra-pure nitrogen. One liter of a dilute solution of purified diaspirin cross-linked hemoglobin in lactated Ringer's solution was deoxygenated by recirculatiαn through a membrane oxygenator charged with ultra-pure nitrogen. The deoxygenated diaspirin cross-linked hemoglobin solution was sealed in screw-capped cuvettes which were stored at 25 °C. Despite the efforts to exclude oxygen, the sample initially contained 20% oxy diaspirin cross-linked hemoglobin, 5.5% met- and 73.7% deoxy diaspirin cross-linked hemoglobin. At five days no detectable oxy diaspirin cross-linked hemoglobin was present and the methemoglobin had risen to 32.5%. The balance was in the deoxy state and total hemoglobin was unchanged (Table 1) . These results illustrate the deoxygenation of a hemoglobin solution by the oxidation reaction during the oxygen scavenging phase. In subsequent measurements at days 8, 50 and 72 the methemoglobin steadily decreased. See FIG. 1. It is important to observe the actual concentration changes of all three hemoglobin forms and total hemoglobin during the autoreduction rather than percent changes. If methemoglobin were precipitating the percent of that ccrponent and the total hemoglobin concentration would fail. The concentration data in Table 1, show the essentially quantitative autoreduction of methemoglobin to deoxyhemoglobin whilethe total concentration ofdiaspirin cross-linkedhemoglobin retrained constant. TABLE 1 Changes in Percent Content and Micrσmolar Concentrations of Hemoglobin Moieties in a Solution of Diaspirin Cross-Linked Hemoglobin in Lactated Ringer's Sealed in a Cuvette at 25 * C PERCENT OF TOTAL DIASPIRIN CROSS-LINKED HEMOGLOBIN MICRCMOLAR CONCENTRATION DAY met oxy deoxy met oxy deoxy ND = not detected. Example 2 In this experiment, efforts were taken to ensure that the samples were stored insufficiently oxygen impermeable containers to observe autoreduction and obtain an estimate of experimental error in these studies, λ dilute solution of diaspirin cross- linked hemoglobin in * lactated Ringer's was prepared and deoxygenated as described in Example 1. Although an increase in the oxyhemoglobin derivative on day one (FIG.2, Table 2) indicated oxygen leaks, the results obtained •** . in Example 1 with respect to the quantitative conversion of Fe- methemoglobin to Fεr * deoxyhemoglobin were reproduced in the samples prepared within a reasonable degree of precision (see + S.D. bars in FIG. 2). The mean values of the percent content and micrcmolar concentrations of the hemoglobin moieties in the sealed cuvettes (N=4) are given in Table 2. TABLE 2 Changes inMean Percent of Total Diaspirin Cross-Linked Hemoglobin andMicrcmolar Concentration of HemoglobinMoieties at 25 * C in Screw-Capped Cuvettes Containing a Solution of Diaspirin Cross- Linked Hemoglobin in Lactated Ringer's PERCENT OF TOTAL DIASPIRIN CROSS-LINKED HEMOGLOBIN MICRCMOLAR CCflCENTRATION DAY met ox deox met deox ND = not detected. Exmp2e_ In the previous examples of the autoreduction reaction in oxygen iirpermeable systems the diaspirin cross-linked hemoglobin was in a lactated Ringer's medium. To ensure that the observed autoreduction effect was not due to a component in the lactated Ringer's, diaspirin cross-linked hemoglobin was exchanged into phosphate (Fo buffer. Ηre ty ml of 10 g/dl diaspirin cross- linked hemoglobin in lactated Ringer's was diluted to one liter with lOπM P0 4 ; ~~ i = 7.40. This fifty-fold dilution was a 98% change of medium. This diluted solution was diafiltered vs. five liters of the same phosphate buffer to effect a further theoretical 99% change in composition of the buffer to phosphate buffer. This solution of diaspirin cross-linked hemoglobin in phosphate was deoxygenated and a number of screw-capped cuvettes were filled, and sealed as described in Example 1. The characteristic pattern of oxidation followed by autoreduction was observed at faster oxidation and reduction rates relative to Examples 1 and 2. The data from one representative cuvette are given in Table 3 and FIG. 3. The methemoglobin level fell 36.5% (9.3-μM) in twenty-five days. TABLE 3 Changes in Percent Content and Micrcmolar Concentration of Hemoglobin Moieties at 25 * C in Screw-Capped Cuvette Containing Diaspirin Cross-Linked Hemoglobin in Phosphate Buffer EERCHiT OF TOTAL DIASPIRIN ND = not detected. Example 4 The results of this experiment showed that a solution of hemoglobin with a high initial oxygen content would, over a period of time, oxidativel , deoxygenate and begin spontaneous autoreduction. A solution of diaspirin cross-linked hemoglobin (27 -μM) in lactated Ringer's was sealed in a cuvette with no head space and kept at 25"C. After oxidizing to greater than 60% methemoglobin in four days and concurrently deoxygenating the solution, only43.1% methemoglobin was present, with no detectable oxy- form, at a day twenty-eight measurement (Table 4; FIG. 4). Although the experiment was not carried any further, it is anticipated that the desired less than 15% methemoglobin level would have been achieved. TABLE 4 Changes in Percent Content and Micrcmolar Concentrations of Hemoglobin Moieties at 25 * C in a Sealed Cuvette Containing ϋndeoxygenated Diaspirin Cross-Linked Hemoglobin in Lactated Ringer's ND - not detected. Example 5 The previous examples demonstrate that spontaneous autoreduction occurs with dilute hemoglobin solutions (approximately 40 -μM; 0.29 g/dl of hemoglobin) stored in oxygen impermeable containers. In this experiment we assessed when autoreductionwould occur using aconcentrated hemoglobin solution (10 g/dl). All the experimental components necessaryto deoxygenate and package the diaspirin cross-linked hemoglobin solution were asseπbled in a gloved isolator chamber. The isolator was sealed and purge with low-oxygen grade nitrogen to 0.017 ppro oxygen. The lOg/dl diaspirin cross-linked hemoglobin solution was deoxygenated to two percent oxygen. The test group flexible containers (150ml internal volune) were filled with approximately 50 ml of deoxygenated diaspirin cross-linked hemoglobin each and then sealed in substantially oxygen iπpermeable foil pouches. T o groups of control units were filled under aπfaient ox gen conditions so the hemoglobin was equilibrated with air oxygen. One group of control units (Ambient Pouched) was sealed in foil pouches and the other (Aπibient Not Pouched) was not sealed in a foil pouch. All units were stored in a 25 * C incubator. At intervals, duplicate packages were pulled frcm each group and sanples were taken from each flexible container with syringe and needle. Aliquots of the 10 g/dl samples were filtered, diluted 50X in phosphate buffer and spectrophotometrically analyzed for methemoglobin content. After an initial three day oxidation phase, spontaneous 5 autoreduction of methemoglobin was evident in the deoxygenated test group. Over the next sixty days the methemoglobin fell 17.7% in the deoxygenated solution while the oxygenated control group solutions continued to oxidize unabated to over ninety percent methemoglobin (Table 5; FIG. 5). Although the experiment was 10 terminated after 63 days, it would be anticipated that the 15% methemoglobin level preferred for an oxygen-carrying solution would have been reached. TABLE 5 Changes in Percent Methemoglobin Content in 10 g/dl Solutions of •*•5 DiaspirinCross-LinkedHemoglobinin LactatedRinger's Packaged In Flexible Containers 0 5 PRE* - preprocessing; the level of methemoglobin before 0 deoxygenation and packaging. 1 POST** = post-processing; the level of methemoglobin after deoxygenation and packaging were completed. Example 6 Plastic bags were filled with 50 ml of solution and sealed in foil pouches. The packaging operation was carried out in an. isolator continuously purged with ultra-pure nitrogen. The isolator technology described in Exanple 5 was again used in this experiment. In this example, however, the isolator was fogged with H after sealing to sterilize all components used in the packaging operation and more rigorous efforts were employed to purge oxygen from the isolator, the packaging containers and the hemoglobin solution. After fogging, the isolator was purged with low-C^ grade nitrogen. The purge line was then switched to ultra-pure nitrogen with an in-line oxygen trap and the isolator was purged further. All coπpαnents were carefully purged with the same ultra-pure nitrogen. Additionally, Ageless (Mitsubishi Chemical Co., Inc.) oxygen absorbing packets were added to certain outer envelopes to further reduce oxygen in the container. The control group did not receive oxygen absorbing packets. They were stored at 25 * C. One or four packets were added to the outer envelopes of the two 25 * C test groups. One packet per container was included in another test group that was stored at 5 * C. In contrast to the results observed in Exanple 5 almost no increase in methemoglobin was observed over the first three days in sanples from any of the test or control groups in this experiment. This result indicated that the initial solution oxygen level was sufficiently low to only allow a rate of autoxidationessentiallyequal to the rate of autoreduction (Table 6; FIG. 6). Autoreduction was evident on day three in the units from the 25 * C test group containing four oxygen absorbing packets. Methemoglobin could not be detected, after 32 or 56 days, in any units from the 25 * C test group containing one Ageless (Mitsubishi Chemical Co.) packet or the control group. Hemoglobin oxidation continued to day five in the 5 * C stored units and remained at the five day level for the remainder of the study (56 days). Duplicate sanples from each test and control group were submitted for sterility testing and were found to be negative in aerobic and anaerobic culture and did not exceed minimi-m acceptable pyrogen levels. TABLE 6 Ch a nges in Percent Methemoglobin Content In 10 g/dl Solutions ofD.aspirin Cross-LinkedHemoglobin inLactated Ringer's Packaged In Flexible Containers PRE* = preprocessing; the level of methemoglobin before deoxygenation and packaging. POST** = post-processing; the level of methemoglobin after deoxygenation and packaging were ccnpleted. NS = not sampled. Example 7 The purpose of this experiment was to study the temperature dependence of the hemoglobin oxidation and reduction reactions that take place during storage in the system. Again, a 10 g/dl solutionof diaspirin cross-linked hemoglobinin lactated Ringer's was packaged in flexible containers and foil pouches using the isolator technology described in Example 5 and the more rigorous steps to exclude oxygen described in Exanple 6. Four groups cf test units were packaged, each unit containing one 200 ml capacity oxygen-absorbing packet. The test groups were stored at 5 * C, 25 * C, 30 * C, 45 * C respectively. Control group units were stored at 25 * C without Ageless (Mitsubishi Chemical Co., Inc.) packets. Duplicate samples from each group were submitted for sterility and pyrogen testing. The data from this experiment are given in Table 7 and FIG. 7. Results at 25 * C were similar to those obtained in Exaπples 5 and 6. The 45 * C response was particularly notable since the oxidative deoxygenation phase required less than a day to complete before the onset of autoreduction. All sanples submitted were found to be sterile in aerobic and anaerobic culture and nαn- pyrogenic TABLE 7 Changes in Percent Methemoglobin Content in a Solution of lOg/dl - - * => * - - - - * - - * » ' * - ERE* = preprocessing; the level of methemoglobin before deoxygenation and packaging. s POST** = post-processing; the level of methemoglobin after deoxygenation and packaging were completed. *** = measurements to determine hemoglobin moieties collected on a Cary 2200 from day 59 to the end of study. Previous measurements were from a Hewlett-Packard 8451A instrument. ND = not detected. NS = not sampled. Example 8 In this experiment we evaluated whether inclusion of oxygen absorbing packets in overpouch may be beneficial over a long storage interval. The test groups in this experiment contained one, two or four type S-200 Ageless (Mitsubishi Chemical Co.) packets in the package head space corresponding to 200, 400 or 800 ml of oxygen absorbing capacity, respectively. Once again, a 10 g/dl solution of diaspirin cross-linked hemoglobin in lactated Ringer's was packaged in flexible containers and foil pouches -using the isolator technology described in Exanple 5 and the more rigorous steps to exclude oxygen described in Exanple 6. The study was designed for a one year duration. There may have been a small effect on the rate of autoreduction comparing control group sample with sanples containing oxygen absorbing packets, but essentially all groups displayed virtually identical autoxidation-autoreduction behavior (Table 8; FIG. 8). TABLE 8 Changes in Percent Methemoglobin Content In a Solution of 10 g/dl Diaspirin Cross-Linked Hemoglobin in Lactated Ringer's Packaged in Flexible Containers PRE* = preprocessing; the level of methemoglobin before deoxygenation and packaging. POST** = post-processing; the level of methemoglobin after deoxygenation and packaging were completed. Sanples from exaπples 7 and 8 were assayed for enzymes known to protect hemoglobin against oxidative damage. See Table 9. TABLE 9 Activities 1 of Reductive Enzymes per Gram of Hemoglobin GLUTATHIONE METHEMOGLOBIN TYPE OF HEMOGLOBIN REDUCTASE REDUCTASE HEMOGLOBIN (g/100 iriL) No EAD With FAD Activity is defined on the basis that one unit of enzyme catalyzes the conversion of 1 umole of substrate per minute. In ancillary studies of parallel samples of diaspirin cross- linked hemoglobin, it has been shown that NADH-methemoglobin reductase, catalase, and superoxide dismutase activities could not be detected. The absence of normal reductive enzymatic activity in these sanples confirms that autoreduction of hemoglobin -under the conditions described in this Invention is independent of entyme systems present in unpurified samples. Although, the invention has been shown in connection with certain specific embodiments, it will be readily apparent to those skilled in the art that various changes in formand arrangement of steps can be made to suit requirements without departing from the spirit and scope of the invention.

Claims: WE CLAIM: 1. A purified hemoglobin based composition comprising: a) autoreduced iron in the heme group of hemoglobin, and b) having a sufficiently low level of methemoglobin for the composition to act as an oxygen carrier when administered to a patient. 2. The composition of Claim 1 wherein the percent of methemoglobin is not greater than about 50% of total hemoglobin at the time of administration to a patient. 3. The composition of Claim 1 wherein the percent of methemoglobin is not greater than about 15% of total hemoglobin at the time of administration to a patient. 4. A method to prepare a hemoglobin based composition comprising: a) adding a purified hemoglobin solution to an oxygen impermeable container, and b) storing said container at a temperature of about 5°C to about 45°C for a sufficient time to permit autoreduction of sufficient methemoglobin for the composition to function as an oxygen carrying solution upon administration to a patient. 5. A purified hemoglobin based composition made by the method of Claim 4. 6. The method of Claim 4 wherein the percent of said methemoglobin is not greater than about 50% of total hemoglobin at the time of administration to a patient. 7. The method of Claim 4 wherein the percent of said methemoglobin is not greater than about 15% of total hemoglobin at the time of administration to a patient. 8. The method of Claim 4 wherein said hemoglobin based solution is stored at from between about -80°C to 45°C, once methemoglobin concentration is sufficiently low to allow said hemoglobin solution to effectively function as an oxygen carrying solution. 9. A method to store a purified hemoglobin based composition having sufficiently low levels of methemoglobin to effectively function as an oxygen carrying solution upon administration to a patient comprising; a) adding purified substantially deoxygenated hemoglobin based composition to an oxygen impermeable container; and b) storing said container at from between 5°C to 45°C for sufficient time to permit the autoreduction of methemoglobin. 10. The method of Claim 9 wherein the percent of said methemoglobin is not greater than about 50% of total hemoglobin at the time of administration to a patient. 11. The method of Claim 9 wherein the percent of said methemoglobin is not greater than about 15% of total hemoglobin at the time of administration to a patient. 12. The method of Claim 9 wherein said hemoglobin based solution is stored at from between about -80°C to 45°C, once methemoglobin concentration is sufficiently low to allow said hemoglobin solution to effectively function as an oxygen carrying solution.

Inventors: KANDLER RICHARD L, SPICUSSA JOHN C, KANDLER, RICHARD, L., SPICUSSA, JOHN, C.
Applicants: BAXTER INT, BAXTER INTERNATIONAL INC.
Application year: 1991
Main classification: A61K37
IPC codes: A61K38, A61P7